International collaboration for the treatment of endometrial cancer, led by the ongoing PORTEC-4a trial, may lead to more efficient therapy strategies, hopes Carien Creutzberg, MD, PhD, of the Leiden University Medical Center, Leiden, Netherlands. Real-time analysis of molecular subgroups can speed up the treatment ‘profiling’ process, while smaller phase II trials are paving the way for treatment against advanced or recurrent disease.